| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
1 Oncology Department, University of Leicester, Leicester; Departments of 2 Radiology and 3 Surgery, University Hospitals of Leicester, Leicester; and 4 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
Curcumin, a polyphenolic antioxidant derived from a dietary spice, exhibits anticancer activity in rodents and in humans. Its efficacy appears to be related to induction of glutathione S-transferase enzymes, inhibition of prostaglandin E2 (PGE2) production, or suppression of oxidative DNA adduct (M1G) formation. We designed a dose-escalation study to explore the pharmacology of curcumin in humans. Fifteen patients with advanced colorectal cancer refractory to standard chemotherapies consumed capsules compatible with curcumin doses between 0.45 and 3.6 g daily for up to 4 months. Levels of curcumin and its metabolites in plasma, urine, and feces were analyzed by high-pressure liquid chromatography and mass spectrometry. Three biomarkers of the potential activity of curcumin were translated from preclinical models and measured in patient blood leukocytes: glutathione S-transferase activity, levels of M1G, and PGE2 production induced ex vivo. Dose-limiting toxicity was not observed. Curcumin and its glucuronide and sulfate metabolites were detected in plasma in the 10 nmol/L range and in urine. A daily dose of 3.6 g curcumin engendered 62% and 57% decreases in inducible PGE2 production in blood samples taken 1 hour after dose on days 1 and 29, respectively, of treatment compared with levels observed immediately predose (P < 0.05). A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract. PGE2 production in blood and target tissue may indicate biological activity. Levels of curcumin and its metabolites in the urine can be used to assess general compliance.
This article has been cited by other articles:
|
|
 |
|
  M. Narasimhan and S. Ammanamanchi Curcumin Blocks RON Tyrosine Kinase-Mediated Invasion of Breast Carcinoma Cells Cancer Res., July 1, 2008; 68(13): 5185 - 5192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chadalapaka, I. Jutooru, S. Chintharlapalli, S. Papineni, R. Smith III, X. Li, and S. Safe Curcumin Decreases Specificity Protein Expression in Bladder Cancer Cells Cancer Res., July 1, 2008; 68(13): 5345 - 5354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Begum, M. R. Jones, G. P. Lim, T. Morihara, P. Kim, D. D. Heath, C. L. Rock, M. A. Pruitt, F. Yang, B. Hudspeth, et al. Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 196 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Weisberg, R. Leibel, and D. V. Tortoriello Dietary Curcumin Significantly Improves Obesity-Associated Inflammation and Diabetes in Mouse Models of Diabesity Endocrinology, July 1, 2008; 149(7): 3549 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Vareed, M. Kakarala, M. T. Ruffin, J. A. Crowell, D. P. Normolle, Z. Djuric, and D. E. Brenner Pharmacokinetics of Curcumin Conjugate Metabolites in Healthy Human Subjects Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1411 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Subramaniam, R. May, S. M. Sureban, K. B. Lee, R. George, P. Kuppusamy, R. P. Ramanujam, K. Hideg, B. K. Dieckgraefe, C. W. Houchen, et al. Diphenyl Difluoroketone: A Curcumin Derivative with Potent In vivo Anticancer Activity Cancer Res., March 15, 2008; 68(6): 1962 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beliveau and D. Gingras Role of nutrition in preventing cancer Can Fam Physician, November 1, 2007; 53(11): 1905 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zeng, F. Qiu, Y. Liu, G. Qu, and X. Yao Isolation and Identification of Phase 1 Metabolites of Demethoxycurcumin in Rats Drug Metab. Dispos., September 1, 2007; 35(9): 1564 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pugazhenthi, L. Akhov, G. Selvaraj, M. Wang, and J. Alam Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in mouse beta-cells Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E645 - E655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Sandur, M. K. Pandey, B. Sung, K. S. Ahn, A. Murakami, G. Sethi, P. Limtrakul, V. Badmaev, and B. B. Aggarwal Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism Carcinogenesis, August 1, 2007; 28(8): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B. B. Aggarwal, and Y. Kondo Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways Mol. Pharmacol., July 1, 2007; 72(1): 29 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Salvioli, E. Sikora, E. L. Cooper, and C. Franceschi Curcumin in Cell Death Processes: A Challenge for CAM of Age-Related Pathologies Evid. Based Complement. Altern. Med., June 1, 2007; 4(2): 181 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, Z. Zhang, D. L. Hill, H. Wang, and R. Zhang Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway Cancer Res., March 1, 2007; 67(5): 1988 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, T. M. C. Tan, and L.-Y. Lim Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats Drug Metab. Dispos., January 1, 2007; 35(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Choi, Y.-S. Chun, S.-W. Kim, M.-S. Kim, and J.-W. Park Curcumin Inhibits Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear Translocator: A Mechanism of Tumor Growth Inhibition Mol. Pharmacol., November 1, 2006; 70(5): 1664 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohori, H. Yamakoshi, M. Tomizawa, M. Shibuya, Y. Kakudo, A. Takahashi, S. Takahashi, S. Kato, T. Suzuki, C. Ishioka, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther., October 1, 2006; 5(10): 2563 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, Q. Wang, K. L. Ives, and B. M. Evers Curcumin Inhibits Neurotensin-Mediated Interleukin-8 Production and Migration of HCT116 Human Colon Cancer Cells. Clin. Cancer Res., September 15, 2006; 12(18): 5346 - 5355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chearwae, S. Shukla, P. Limtrakul, and S. V. Ambudkar Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., August 1, 2006; 5(8): 1995 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sikora, A. Bielak-Zmijewska, A. Magalska, K. Piwocka, G. Mosieniak, M. Kalinowska, P. Widlak, I. A. Cymerman, and J. M. Bujnicki Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. Mol. Cancer Ther., April 1, 2006; 5(4): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chirnomas, T. Taniguchi, M. de la Vega, A. P. Vaidya, M. Vasserman, A.-R. Hartman, R. Kennedy, R. Foster, J. Mahoney, M. V. Seiden, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther., April 1, 2006; 5(4): 952 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Izzo, U. Malhotra, T.-T. Wu, J. Ensor, R. Luthra, J. H. Lee, S. G. Swisher, Z. Liao, K.S. C. Chao, W. N. Hittelman, et al. Association of Activated Transcription Factor Nuclear Factor {kappa}B With Chemoradiation Resistance and Poor Outcome in Esophageal Carcinoma J. Clin. Oncol., February 10, 2006; 24(5): 748 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, D. P. Thomas, X. Zhang, B. W. Culver, B. M. Alexander, W. J. Murdoch, M. N.A. Rao, D. A. Tulis, J. Ren, and N. Sreejayan Curcumin Inhibits Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cell Function and Injury-Induced Neointima Formation Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 85 - 90. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
